Genzyme,
a Sanofi company SNY, announced today
that the U.S. Food and Drug Administration (FDA) has approved AUBAGIO®
(teriflunomide) as a new once-daily, oral treatment indicated for
patients with relapsing forms of multiple sclerosis (MS). AUBAGIO has
shown significant efficacy across key measures of MS disease activity,
including reducing relapses, slowing the progression of physical
disability, and reducing the number of brain lesions as detected by MRI.
AUBAGIO (R) 14mg
“We are very excited to introduce AUBAGIO as a new treatment option
that can make a difference in the lives of people with multiple
sclerosis,” said David Meeker, President and CEO, Genzyme. “The
approval of
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in